FDA grants fast track designation to drug combo for colorectal cancer
Business Announcement
Updates every hour. Last Updated: 22-Dec-2025 09:11 ET (22-Dec-2025 14:11 GMT/UTC)
OKLAHOMA CITY – The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma Health Stephenson Cancer Center. The treatment offers potential hope for patients whose tumors lack a key DNA repair protein called ATM.
A grocery support program based on the low-sodium DASH eating plan that included home-delivered groceries and dietary counseling reduced blood pressure levels in Black adults living in areas where grocery stores were inaccessible or scarce, known as food deserts.
Alzheimer’s Disease (AD), the leading cause of dementia, affects nearly 40 million individuals globally, resulting in a gradual loss of memory and independence. Despite extensive research over the past decades, no treatments have been found that can halt or reverse the progression of this devastating disease. A groundbreaking international study shows how boosting a natural molecule can help restore memory in animal models of Alzheimer’s disease. The new study offers hope for developing new therapies for patients with Alzheimer’s disease.
A study of 400 adults with high blood pressure found that participants were twice as likely to take their blood pressure medication (measured by electronic pill bottles that recorded when bottles were opened) when they could win a daily cash reward compared to people who were not offered a potential reward.
Adults with heart disease prescribed vitamin D in doses tailored to reach blood levels considered optimal for heart health (>40-80 ng/mL) had a reduced risk of heart attack by more than half (52%) compared to those who did not receive monitoring of vitamin D levels.